Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Personalis, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,366 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 32,366 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-05-12 | Direct | 37,500 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 37,500 · Balance 37,500 F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 14,318 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.58 · Expires 2020-05-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 1,872 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.05 · Expires 2021-05-07 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 6,402 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.08 · Expires 2025-05-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 5,604 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2026-05-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 7,032 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.66 · Expires 2027-05-11 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 8,006 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
Keenova Therapeutics plc
Report date November 14, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-14 transaction · row 1
1 source rowRow 1 · 2023-11-14 · Disposition to issuer · Disposed 23,122 · Balance 0 F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland.
F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy.
F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 21:02 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001243399-26-000001 · form4-05142026_090538.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2036-05-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:02 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001243399-26-000001 · form4-05142026_090538.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,366 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:12 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001415889-25-013791 · form4-05202025_080503.xml · derivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:31 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-014046 · form4-05222024_010511.xml · derivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-05-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such Change in Control. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:15 UTC | Personalis, Inc. PSNL · Entity 4572 | PurchaseCommon Stock | 10,000 | $1.67 | $16,700.00 |
DisclosureSEC source: 0001415889-24-006773 · form4-03052024_100343.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,116 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.65 to $1.67. The price reported above reflects the weighted average price. The reporting persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:14 UTC | Keenova Therapeutics plc MNKTQ · Entity 28960 | Disposition to issuerOrdinary Shares | 23,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-119115 · tm2330745-10_4seq1.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2 · kind: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3 · kind: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:52 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Disposition to issuerOrdinary Shares | 26,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-076472 · tm2320181-4_4seq1.xml · nonDerivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,122 F1 · shares: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · price: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · balance_after: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:52 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,154 | $1.28 | $4,037.12 |
DisclosureSEC source: 0001104659-23-076472 · tm2320181-4_4seq1.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,399 Read SEC document |
| May 17, 2023 Filed May 20, 2023 00:45 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-23-031284 · doc4.xml · derivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such Change in Control. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:03 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 26,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001547 · tm231710-8_4seq1.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,553 F1 · shares: The reported ordinary shares represent restricted stock units ("RSUs"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 26,277 newly awarded RSUs and 26,276 RSUs previously reported in Table II. Read SEC document |
| August 16, 2022 Filed Sep 15, 2022 01:17 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 22,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-100152 · tm2225913-5_4seq1.xml · derivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 Underlying: Ordinary Shares · 22,533 shares Expires not disclosed F1 · derivative.exercise_price: As previously disclosed, on August 16, 2022, Dr. Woodrow A. Myers, Jr. agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Dr. Myers 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.exercise_date: As previously disclosed, on August 16, 2022, Dr. Woodrow A. Myers, Jr. agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Dr. Myers 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.expiration_date: As previously disclosed, on August 16, 2022, Dr. Woodrow A. Myers, Jr. agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Dr. Myers 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 01:14 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | GrantRestricted Stock Units · Derivative | 48,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025537 · doc4.xml · derivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,809 Underlying: Ordinary Shares · 48,809 shares Expires not disclosed F1 · derivative.exercise_price: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.exercise_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.expiration_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. Read SEC document |
| May 17, 2022 Filed May 19, 2022 23:45 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 15,035 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-22-030775 · doc4.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,035 Underlying: Common Stock · 15,035 shares Expires 2032-05-17 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control. Read SEC document |
| May 17, 2022 Filed May 19, 2022 23:45 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 10,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030775 · doc4.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,116 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:28 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 4,229 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001209191-21-033498 · doc4.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,229 Underlying: Common Stock · 4,229 shares Expires 2031-05-14 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:28 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 2,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033498 · doc4.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,346 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control. Read SEC document |
| March 06, 2021 Filed Mar 8, 2021 23:14 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (Right to Buy) · Derivative | 3,719 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001209191-21-018685 · doc4.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,719 Underlying: Common Stock · 3,719 shares Expires 2031-03-06 F2 · derivative.exercise_date: The shares subject to the option vest in 3 annual installments starting on March 6, 2022. Read SEC document |
| March 06, 2021 Filed Mar 8, 2021 23:14 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 2,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018685 · doc4.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest in 3 annual installments with the first installment vesting on March 6, 2022. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 8,006 | $0.00 Strike: $60.66 | $0.00 |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · derivative · entry 6 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 8,006 shares Expires 2027-05-11 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,032 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · derivative · entry 5 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 7,032 shares Expires 2026-05-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 5,604 | $0.00 Strike: $84.08 | $0.00 |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · derivative · entry 4 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,604 shares Expires 2025-05-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 6,402 | $0.00 Strike: $67.05 | $0.00 |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · derivative · entry 3 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 6,402 shares Expires 2021-05-07 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 1,872 | $0.00 Strike: $61.58 | $0.00 |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 1,872 shares Expires 2020-05-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 22:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 14,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000693 · edgar.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. Read SEC document |
| May 10, 2018 Filed May 14, 2018 22:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 2,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000381 · edgar.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,318 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on May 1, 2019, May 1, 2020, and May 1, 2021. Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:50 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 3,900 | $63.93 | $249,342.60 |
DisclosureSEC source: 0000950138-17-000625 · edgar.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:11 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 8,006 | Not disclosed Strike: $60.66 | Not disclosed |
DisclosureSEC source: 0000950138-17-000435 · edgar.xml · derivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006 Underlying: Express Scripts Holding Company Common Stock · 8,006 shares Expires 2027-05-11 F2 · price: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020. F2 · derivative.exercise_date: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:11 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 1,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000435 · edgar.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,400 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on May 1, 2018, May 1, 2019, and May 1, 2020. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionNon-Qualified Stock Option (Right-to-Buy) · Derivative | 4,000 | Not disclosed Strike: $61.58 | Not disclosed |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · derivative · entry 7 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,872 Underlying: Express Scripts Holding Company Common Stock · 4,000 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Grant of stock options pursuant to the Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2014, May 1, 2015, and May 1, 2016. F4 · derivative.exercise_date: Grant of stock options pursuant to the Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2014, May 1, 2015, and May 1, 2016. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionNon-Qualified Stock Option (Right-to-Buy) · Derivative | 6,870 | Not disclosed Strike: $52.53 | Not disclosed |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · derivative · entry 6 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 6,870 shares Expires 2019-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Grant of stock options pursuant to the Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2013, May 1, 2014, and May 1, 2015. F3 · derivative.exercise_date: Grant of stock options pursuant to the Express Scripts, Inc. 2011 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2013, May 1, 2014, and May 1, 2015. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionNon-Qualified Stock Option (Right-to-Buy) · Derivative | 1,166 | Not disclosed Strike: $57.59 | Not disclosed |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · derivative · entry 5 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 1,166 shares Expires 2018-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Grant of stock options pursuant to the Express Scripts, Inc. 2000 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2012, May 1, 2013, and May 1, 2014. F2 · derivative.exercise_date: Grant of stock options pursuant to the Express Scripts, Inc. 2000 Long-Term Incentive Plan. Vested in three (3) equal installments on May 1, 2012, May 1, 2013, and May 1, 2014. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | SaleCommon Stock | 12,036 | $70.40 | $847,382.54 |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · nonDerivative · entry 4 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,752 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.39 to $70.406, inclusive. The Reporting Person undertakes to provide to Express Scripts Holding Company, any security holder of Express Scripts Holding Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionCommon Stock | 4,000 | $61.58 | $246,320.00 |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · nonDerivative · entry 3 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionCommon Stock | 6,870 | $52.53 | $360,881.10 |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · nonDerivative · entry 2 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Exercise / conversionCommon Stock | 1,166 | $57.59 | $67,149.94 |
DisclosureSEC source: 0000950138-16-001317 · edgar.xml · nonDerivative · entry 1 MYERS WOODROW A JR · CIK 0001243399 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.